Summary Deep Track Capital, a significant shareholder of Dynavax Technologies Corp (DVAX) with a 14.82% stake, has issued a letter to fellow shareholders advoca
Deep Track Capital, LP, (together with its affiliates, ”Deep Track” or ”we”), one of the largest shareholders of Dynavax Technologies Corporation (NASD
Dynavax Technologies Corporation has encouraged its shareholders to cast their votes in favor of re-electing its four current directors. The directors up for re
PR NewswireEMERYVILLE, Calif., June 9, 2025
Dynavax's Strategy is Delivering Significant Long-Term Stockholder ValueDynavax's Nominees Are Vastly Superior
Deep Track Capital, LP, (together with its affiliates, ”Deep Track” or ”we”), one of the largest shareholders of Dynavax Technologies Corporation (NASD
Summary Deep Track Capital, a significant shareholder of Dynavax Technologies Corp (DVAX), has issued a statement criticizing the recent report by Institutional
Deep Track Capital, LP, (together with its affiliates, ”Deep Track” or ”we”), one of the largest shareholders of Dynavax Technologies Corporation (NASD
Deep Track Capital criticizes Institutional Shareholder Services (ISS) for inadequate analysis of Dynavax Technologies (DVAX) board performance. The inv
PR NewswireEMERYVILLE, Calif., May 23, 2025
ISS Recognizes There is No Case for ChangeDynavax's Superior Strategy and Current Board are Best Equipped to De
Deep Track Capital, LP, (together with its affiliates, ”Deep Track” or ”we”), one of the largest shareholders of Dynavax Technologies Corporation (NASD
PR NewswireEMERYVILLE, Calif., May 12, 2025
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stoc
PR NewswireEMERYVILLE, Calif., May 7, 2025
In the news release, Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Resu
Dynavax Technologies (DVAX) revises stockholder value metrics to over $900 million and 62% return. Q1 2025 revenue jumps 34% YoY to $68.2 million, drive
PR NewswireEMERYVILLE, Calif., May 6, 2025
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-
Deep Track Capital, LP, (together with its affiliates, ”Deep Track” or ”we”) one of the largest shareholders of Dynavax Technologies Corporation (NASDA
PR NewswireEMERYVILLE, Calif., May 1, 2025
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver
PR NewswireEMERYVILLE, Calif., April 29, 2025
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD
Dynavax Technologies (DVAX) sees a strong performance with its HEPLISAV-B® vaccine, projecting $305-$325 million in revenue for 2025 after achieving $268